Meta-analysis - Eltrombopag

This study has been completed.
Information provided by:
GlaxoSmithKline Identifier:
First received: November 4, 2010
Last updated: November 3, 2011
Last verified: November 2011

The purpose of the meta-analysis was to explore the efficacy of eltrombopag versus placebo (standard of care)

Condition Intervention
Drug: Eltrombopag
Drug: Placebo

Study Type: Observational
Study Design: Time Perspective: Retrospective
Official Title: Systematic Review of the Clinical and Cost Effectiveness of Treatments for Idiopathic (Immune) Thrombocytopenic Purpura (ITP): Direct Meta Analysis

Resource links provided by NLM:

Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • >=50 Gi/L platelet count to <400 Gi/L [ Time Frame: 43 days ] [ Designated as safety issue: No ]

Enrollment: 1
Study Start Date: August 2009
Study Completion Date: October 2009
Primary Completion Date: October 2009 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Eltrombopag & standard of care Drug: Eltrombopag
Eltrombopag 50mg & standard of care
Standard of care Drug: Placebo
Placebo + standard of care

Detailed Description:

Meta-analysis of three studies: Bussell 2007 & Bussell 2009 & RAISE (TRA102537).


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Meta-analysis: A systematic review was conducted to obtain all relevant evidence relating to eltrombopag and relevant studies were selected


Inclusion Criteria:

  • Adults with ITP
  • Received a pre-specified treatment
  • Prospective clinical studies with at least 10 patients

Exclusion Criteria:

  • Subjects with ITP due to other causes
  Contacts and Locations
Please refer to this study by its identifier: NCT01235988

Sponsors and Collaborators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

No publications provided

Responsible Party: Cheri Hudson; Clinical Disclosure Advisor, GSK Clinical Disclosure Identifier: NCT01235988     History of Changes
Other Study ID Numbers: 114013
Study First Received: November 4, 2010
Last Updated: November 3, 2011
Health Authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency

Additional relevant MeSH terms:
Purpura, Thrombocytopenic
Blood Coagulation Disorders
Hematologic Diseases
Thrombotic Microangiopathies
Blood Platelet Disorders
Immune System Diseases
Pathologic Processes
Skin Manifestations
Signs and Symptoms processed this record on April 17, 2014